Evidence map›Paper›PMID 35348320›Full record

ReviewACS nano2022

Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs.

André E Nel, Kuo-Ching Mei, Yu-Pei Liao, Xiangsheng Liu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS nano, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Genes & diseases · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

André E NelDivision of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095, United States.ORCID 0000-0002-5232-4686
Kuo-Ching MeiDivision of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095, United States.ORCID 0000-0001-6045-2154
Yu-Pei LiaoDivision of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095, United States.ORCID 0000-0001-7239-9426
Xiangsheng LiuDivision of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095, United States.
California NanoSystems Institute · US

Funding

Use of a Nano-Enabled Platform for Pancreatic Cancer ImmunotherapyR01CA247666 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS, ZINK, JEFFREY I · 2020 to 2024
$2.6M
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas CancerU01CA198846 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, MENG, HUAN · 2015 to 2019
$2.4M
NCI NIH HHS R01 CA247666NCI NIH HHS U01 CA198846
6 · The paper itself

Abstract

In addition to the contribution of cancer cells, the solid tumor microenvironment (TME) has a critical role in determining tumor expansion, antitumor immunity, and the response to immunotherapy. Understanding the details of the complex interplay between cancer cells and components of the TME provides an unprecedented opportunity to explore combination therapy for intervening in the immune landscape to improve immunotherapy outcome. One approach is the introduction of multifunctional nanocarriers, capable of delivering drug combinations that provide immunogenic stimuli for improvement of tumor antigen presentation, contemporaneous with the delivery of coformulated drug or synthetic molecules that provide immune danger signals or interfere in immune-escape, immune-suppressive, and T-cell exclusion pathways. This forward-looking review will discuss the use of lipid-bilayer-encapsulated liposomes and mesoporous silica nanoparticles for combination immunotherapy of the heterogeneous immune landscapes in pancreatic ductal adenocarcinoma and triple-negative breast cancer. We describe how the combination of remote drug loading and lipid bilayer encapsulation is used for the synthesis of synergistic drug combinations that induce immunogenic cell death, interfere in the PD-1/PD-L1 axis, inhibit the indoleamine-pyrrole 2,3-dioxygenase (IDO-1) immune metabolic pathway, restore spatial access to activated T-cells to the cancer site, or reduce the impact of immunosuppressive stromal components. We show how an integration of current knowledge and future discovery can be used for a rational approach to nanoenabled cancer immunotherapy.

Indexed as

Immunogenic Cell DeathPancreatic NeoplasmsCell Line, TumorDrug CarriersHumansImmunotherapyLipid BilayersTumor MicroenvironmentDrug CarriersLipid Bilayerscombination therapyimmune escapeimmune landscapesimmune suppressionimmunogenic cell deathliposomesnanocarrierpancreas cancersilicasomesspatial distributiontriple-negative breast cancer

Identifiers

PMID35348320
PMCPMC9519818
OpenAlexW4221070980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.